Smart dosing of blood thinner could save kidneys in children
NCT ID NCT05672550
First seen Nov 20, 2025 · Last updated Jun 22, 2026 · Updated 26 times
Summary
This study tested a personalized way to dose the blood thinner enoxaparin in 50 children after kidney transplant. The goal was to prevent dangerous blood clots in the new kidney while avoiding excessive bleeding. Doctors used a computer model (Bayesian approach) to adjust doses based on each child's needs, aiming for a precise anti-Xa target. The trial compared this smart dosing to standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PEDIATRIC KIDNEY TRANSPLANT RECIPIENTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Félix Guyon
La Réunion, France
-
Hôpital Mère Enfant
Lyon, France
-
Hôpital Necker - Enfants malades
Paris, Île-de-France Region, 75015, France
-
Hôpital Necker Enfants Malades
Paris, 75015, France
-
Hôpital Pellegrin
Bordeaux, 33000, France
-
Hôpital Robert Debré
Paris, 75019, France
-
Hôpital de Hautepierre
Strasbourg, France
-
Hôpital de la Villeneuve
Montpellier, France
-
Hôpital des Enfants
Toulouse, France
-
Hôtel Dieu
Nantes, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
enoxaparin (a blood thinner)
What this could lead to
If successful, this could lead to safer, more effective blood clot prevention in children after kidney transplant, reducing graft loss.
What could go wrong
This is a small, completed Phase 4 study with only 50 participants. The approach may not work for all children or may still carry bleeding risks.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.